Key points from article :
Tenvie Therapeutics, a US-based biotech company, has launched with an impressive $200 million in funding to develop innovative treatments for neurological, cardiometabolic, and ophthalmic diseases. Headquartered in South San Francisco, Tenvie has acquired small-molecule programs and a seasoned discovery team from Denali Therapeutics. The company aims to combat age-related diseases by addressing three key biological drivers: inflammation, metabolic dysfunction, and lysosomal dysfunction—factors linked to neurodegenerative conditions like Alzheimer’s and Parkinson’s.
Tenvie’s approach sets it apart by focusing on dual-action therapies: brain-penetrant molecules for central nervous system (CNS) diseases and precision-designed molecules for conditions outside the brain. Their leading drug candidates include an NLRP3 inhibitor targeting neuroinflammation and a SARM1 inhibitor aimed at preventing axonal degeneration, both nearing clinical testing. The pipeline also features preclinical programs targeting neuroprotective pathways, alongside undisclosed candidates for cardiometabolic and ophthalmic diseases.
Built on the foundations of Denali Therapeutics, Tenvie benefits from a skilled team, preclinical assets, and a cutting-edge facility. Led by President and Chief Scientific Officer Tony Estrada, the company is committed to transforming the treatment paradigm for neurological diseases, with the goal of improving lives for patients and their families.
The launch was backed by prominent investors, including ARCH Venture Partners, F-Prime Capital, and Mubadala Capital. Industry leaders lauded Tenvie’s deep scientific expertise and its potential to fill critical gaps in care for diseases with limited treatment options. Tenvie is poised to lead the next wave of breakthroughs in neurology and beyond.
